Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
More News: Cardiology | Eating Disorders & Weight Management | Heart | Obesity | Pharmaceuticals | Victoza